Insight Molecular Diagnostics Inc.
IMDX$4.80
$-0.20 (-4.00%)-4.00%
ClosedLoading chart...
IndexN/A
Market Cap0.15B
Enterprise Value0.22B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-4.03
P/S56.37
P/B-7.26
P/C-9.01
EV/EBITDA-4.60
EV/SalesN/A
EPS (ttm)-1.19
EarningsN/A
Gross Margin4.69%
Oper. Margin-754.08%
Profit Margin-1238.52%
Volume0.13M
Shs Outstand0.03B
Change-4.00%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.88M | $1.50M | $958.00K | $2.20M | $1.22M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $1.14M | $1.09M | $976.00K | $778.00K | $1.85M | $344.00K | $559.00K | $580.00K |
| Gross Profit | $740.00K | $413.00K | $-18.00K | $1.42M | $-639.00K | $-344.00K | $-559.00K | $-580.00K |
| Gross Margin | 39.34% | 27.48% | -1.88% | 64.60% | -52.55% | N/A | N/A | N/A |
| Operating Expenses | $61.78M | $25.55M | $17.98M | $55.15M | $29.07M | $21.89M | $14.64M | $18.27M |
| Operating Income | $-61.04M | $-25.14M | $-18.00M | $-53.73M | $-29.71M | $-22.24M | $-15.20M | $-18.85M |
| Operating Margin | -3245.14% | -1672.39% | -1878.60% | -2444.27% | -2443.34% | N/A | N/A | N/A |
| Net Income | $-60.66M | $-27.78M | $-72.90M | $-64.10M | $-29.93M | $-22.33M | $-15.75M | $-19.38M |
| Net Margin | -3225.04% | -1848.37% | -7609.81% | -2916.15% | -2461.51% | N/A | N/A | N/A |
| EPS (Basic) | $-4.66 | $-3.75 | $-20.00 | $-14.40 | $-9.14 | $-8.71 | $-8.32 | $-12.83 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $35.08M | $74.89M | $100.09M | $159.56M | $55.42M | $39.86M | $9.52M | $10.22M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $47.35M | $54.42M | $60.50M | $94.35M | $21.94M | $9.02M | $6.09M | $5.81M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $-12.27M | $20.47M | $39.59M | $65.22M | $33.48M | $30.84M | $3.42M | $4.40M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $-12.27M | $20.47M | $39.59M | $65.22M | $33.48M | $30.84M | $3.42M | $4.40M |
| Total Liabilities & Stockholders Equity | $35.08M | $74.89M | $100.09M | $159.56M | $55.42M | $39.86M | $9.52M | $10.22M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-60.66M | $-27.78M | $-72.90M | $-64.10M | $-29.93M | $-22.33M | $-15.75M | $-19.38M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-20.71M | $-23.32M | $-45.57M | $-35.94M | $-25.98M | $-19.71M | $-11.65M | $-13.38M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conferenceglobenewswire.com iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publicationglobenewswire.com Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolioglobenewswire.com IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paperglobenewswire.com iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grantglobenewswire.com Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistryglobenewswire.com IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantationglobenewswire.com IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantationglobenewswire.com
Show 12 more stories
Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.com iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congressglobenewswire.com Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcriptseekingalpha.com IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercializationglobenewswire.com Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assayglobenewswire.com Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcriptseekingalpha.com IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Resultsglobenewswire.com iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conferenceglobenewswire.com Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Scoreglobenewswire.com Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Reviewdefenseworld.net Head-To-Head Contrast: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)defenseworld.net Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)defenseworld.net
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Discover more
You may be interested in